Costing in Pharma: Batch, Market and the Cost of Being Allowed to Sell
Regulatory and quality are not overhead. They are the cost of being permitted to sell at all, and they vary enormously by market.
Summary
- Pharma costing has two levels. Cost per batch is the one most companies build properly. Cost per market is where the decisions live, and most companies do not build it at all.
- Campaign changeover is fixed per campaign, so short campaigns carry far more of it per unit, and scheduling is a costing decision that should carry a number.
- Quality and regulatory cost is usually apportioned by revenue. Apportioned on tests, batches, filings and audit load instead, it often changes which markets look worth prioritising.
- Tenders and API-to-formulation transfers each need their own treatment: tenders for administration, slow payment and capacity; transfers for a stated basis that does not change quietly.
Pharma looks like manufacturing and costs like something else.
The physical conversion, API and excipients into a finished pack, is a normal manufacturing problem. Everything around it is not. Campaign scheduling, cleaning validation, quality release, stability testing, market-specific registration and the cost of an are all real and large. They are also shared across products in ways that ordinary factory logic does not handle well.
Get the apportionment of that second group wrong and your market-wise profitability will be confidently incorrect.
The cost object is the batch, then the market
Two levels, and most companies build the first properly and the second not at all.
- Cost per batch: what one production campaign consumes.
- Cost per market: that batch cost, plus everything specific to selling it in a particular geography, against what that market actually realises.
The second is where the decisions live. The same product, from the same plant, can earn very differently in the domestic market, a regulated export market, a semi-regulated one, and a government tender.
Building cost per batch
- API and key starting materials. Usually the largest line, and the most volatile. Price moves with supply, and single-source APIs carry a risk premium that is rarely costed.
- Excipients and packaging. Primary pack, pack, inserts, serialisation. Market-specific packaging means the same tablet has different packaging cost by destination.
- Conversion. Direct labour, utilities, equipment time for the campaign.
- Yield loss. Granulation loss, compression rejects, coating defects, in-process rejections, and the samples drawn for testing that never ship. Pharma yields are generally well tracked; the error is more often failing to apply them to cost by product.
- Campaign changeover. This is the pharma-specific one. Cleaning, cleaning validation, line clearance, documentation and the downtime between products. Fixed per campaign, which means it is far heavier per unit on short campaigns.
That last point drives a real commercial consequence. A 50,000-unit campaign and a 500,000-unit campaign of the same product do not have the same unit cost. The same changeover, spread over a tenth of the units, weighs ten times as much on each one. A company taking small orders at standard cost is under-recovering its changeover on every one.
Campaign scheduling is a costing decision
Most pharma companies treat scheduling as a planning function. It is also among the biggest levers on unit cost, and almost nobody prices it.
Every changeover costs cleaning, validation, documentation and lost capacity. Fewer, longer campaigns reduce cost per unit, which is the volume effect in its plainest form. More, shorter campaigns increase it, and improve responsiveness and reduce inventory.
The costing job is to put a number on the trade-off, so the decision gets made deliberately. Weigh cost per changeover × number of changeovers against the inventory and service benefit of running shorter.
Most companies have never calculated cost per changeover, which means the trade-off is being made by default.
Quality and regulatory: the cost of permission
This is where pharma differs most from ordinary manufacturing, and where apportionment matters most.
QA, QC, stability studies, documentation, regulatory affairs, audit readiness and remediation are large, shared, and usually apportioned by revenue.
That is almost always wrong, because what consumes them is not revenue.
Quality and regulatory costs: the usual apportionment basis and the driver that reflects consumption
| Cost | Usual basis | Driver that reflects consumption |
|---|---|---|
| QC testing | Revenue | Tests performed, weighted by method complexity |
| Stability studies | Revenue | Studies running, by product and market |
| Batch release | Revenue | Batches released |
| Documentation and QMS | Revenue | Batches, plus change controls raised |
| Regulatory affairs | Revenue | Filings, variations and renewals by market |
| Audit and remediation | Revenue | Markets serviced, weighted by regulator |
The regulatory line is the one that changes the picture.
A product registered in one semi-regulated market carries a fraction of the regulatory and audit burden of the same product registered in several highly regulated ones.
Apportion that by revenue and your high-value regulated-market sales look as though they carry proportionate cost. Apportion it by filings and audit load and the picture usually shifts, sometimes enough to change which markets you prioritise.
Contribution by market is the number to run on
Market-wise profitability comes down to one line:
Realised price in market − batch cost − market-specific cost = contribution by market
Market-specific cost includes registration amortised over the registration period, variation and renewal costs, market-specific packaging and artwork, and cold chain where applicable. It also covers distributor margin and schemes, freight and duty, local regulatory representation, and the financing cost of the collection period. That last cost varies enormously between a regulated-market distributor and a government tender.
What this typically shows: a market that looks attractive on realised price per pack is far less attractive once registration, audit burden and collection period are loaded onto it. And a lower-price market with low regulatory burden and fast payment can be the better business.
Every line in that sum is caused by selling in that market, so the result is contribution. Load the apportioned share of QA, QC and audit cost from the table above as well and the result is market profit, the number for deciding which markets to prioritise.
Tenders are their own costing problem
Government and institutional tenders have economics unlike any other channel.
- Volume is large and price is thin, so contribution per unit is small, and absolute contribution depends entirely on actually winning and on the volume materialising.
- Administration is heavy. Bid preparation, qualification documentation, sampling, inspection, and compliance reporting through the life of the contract.
- Payment is slow, often very. At a realistic cost of capital, a 150-day collection on a thin-margin tender can consume most of the margin. At 14% a year, 150 days costs about 5.75% of the invoice (14% × 150 ÷ 365). On a tender earning, say, 8% contribution before financing, that is roughly 72% of it.
- And the capacity question is live. A tender that fills otherwise idle capacity is a different proposition from one that displaces higher-contribution commercial business. Cost it both ways before bidding.
Internal transfer prices between API and formulation
For companies doing both, the internal transfer is a costing decision with real consequences.
If the API business supplies the formulation business at full absorbed cost, formulation looks weaker and API looks stronger. At variable cost, the reverse. At market price, each stands alone.
The honest treatment is to report both: each business at a market-equivalent transfer price so each can be evaluated independently, plus a consolidated view at actual cost. Pick one basis for internal reporting, state it, and do not change it quietly, because the transfer price determines which business appears to be working.
Whether to make a given API in-house at all is a separate build or buy question.
Which of your markets deserves the priority?
Take your three highest-volume products.
Build cost per batch including changeover, with yield applied. Then build cost per market for each, with regulatory and audit burden apportioned on filings rather than revenue, and the collection period costed.
Then compare contribution and market profit by market.
Most companies find at least one market they have been prioritising that does not deserve it, and one they have been under-serving that does.
Our Pricing Maturity Assessment is a short read on how your pricing, and the cost base it rests on, holds up.
Frequently asked questions
What is batch costing in pharma?
Building the cost of one production campaign: API and starting materials, excipients and packaging, conversion, yield loss applied by product, and changeover. That covers cleaning, cleaning validation, line clearance, documentation and downtime. Changeover is fixed per campaign, so it weighs most on short ones.
How should regulatory cost be allocated across markets?
On what consumes it rather than on revenue: filings, variations and renewals by market for regulatory affairs, and markets serviced, weighted by regulator, for audit and remediation. A product in several highly regulated markets carries far more of that burden than the same product in one semi-regulated market.
How do you calculate contribution by market in pharma?
Realised price in that market, minus batch cost, minus market-specific cost. Market-specific cost means amortised registration, variations and renewals, market-specific packaging and artwork, and cold chain where needed. It also includes distributor margin and schemes, freight and duty, local regulatory representation, and the financing cost of the collection period.
How useful was this article?
One tap. It tells us what to write more of.
About the author
SRF Capital Studio
The next one
Get what we publish next, by email.
Working notes on raising, borrowing, protecting, growing and structuring capital in India. One email a week at most, and you can leave any time.
We use your address only to send this. See our privacy policy.
We store your address to send you these emails and nothing else. See our privacy policy.